RICHLAND, Wash., Nov. 30, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE
MKT: ISR), a medical technology company and innovator in seed
brachytherapy and medical radioisotope applications for the
treatment of prostate, brain, lung, head and neck and gynecological
cancers, today announced that Tom
LaVoy, Chairman and CEO, and Brien
Ragle, CFO, will present a corporate overview at the 9th
Annual LD Micro Main Event Investor Conference taking place on
December 6-8, 2016 at the Luxe Sunset
Boulevard Hotel, Los Angeles,
CA.
Management will present on Tuesday,
December 6, 2016 at 12:30pm
PT. A live webcast of the presentation will be available at
http://wsw.com/webcast/ldmicro11/isr. For those who are not
available to listen to the live webcast, a replay will be archived
on IsoRay's website at
https://isoray.com/about/investors/events-and-presentations/ for 90
days following the live event.
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is
the sole producer of Cesium-131 brachytherapy seeds, which are
expanding brachytherapy options throughout the body. Learn more
about this innovative Richland,
Washington Company and explore the many benefits and uses of
Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay.
Follow us on Twitter @IsoRay.
Logo - http://photos.prnewswire.com/prnh/20160301/339505LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/isoray-to-present-at-9th-annual-ld-micro-investor-conference-300370390.html
SOURCE IsoRay, Inc.